DeepMind spinout Isomorphic Labs partners with Eli Lilly and Novartis on AI-based drug discovery, with $82.5M paid upfront and $2.9B in performance incentives
Context & Ripple Effects
The Lilly and Novartis collaborations put Isomorphic Labs’ drug-discovery platform into commercial use with two large pharmaceutical partners, pairing a modest upfront payment with much larger milestone-based rewards. Two days later, Demis Hassabis publicly framed the ambition as halving drug-discovery timelines, making the partnerships an early test of that claim.
The company’s later $600M financing round indicates that its pharma-partnership model became part of a broader capital-raising narrative, rather than remaining a one-off research collaboration.
First-order effects
- Isomorphic Labs receives $82.5M upfront and a path to up to $2.9B if agreed development milestones are met, giving its AI drug-discovery work immediate commercial backing.
- Eli Lilly and Novartis gain access to Isomorphic Labs’ platform for discovery work, while retaining the milestone structure to tie most of their spending to results.
Second-order effects
- The milestone-heavy contracts make demonstrable discovery progress central to Isomorphic Labs’ ability to realize the headline value, increasing pressure to convert model capabilities into drug-development outputs.
- Competing AI-drug-discovery vendors will face a clearer procurement benchmark: large pharma partners may favor collaborations that combine platform access with outcome-linked economics.
Third-order effects
- If similar arrangements persist, AI drug discovery could develop around platform companies funded by a mix of venture capital, pharma upfront payments, and downstream development milestones rather than standalone software subscriptions.
- The pattern would shift the sector’s differentiation from model claims toward whether AI platforms can repeatedly meet pharmaceutical development milestones—a standard that remains difficult to establish from partnership announcements alone.
The trend: AI drug-discovery companies are moving toward pharma partnerships that treat model platforms as shared, outcome-linked R&D infrastructure.